Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.

Autor: Vanderheiden A; Center for Childhood Infections and Vaccines (CCIV), Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA., Ralfs P; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA.; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA., Chirkova T; Center for Childhood Infections and Vaccines (CCIV), Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA., Upadhyay AA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Zimmerman MG; Center for Childhood Infections and Vaccines (CCIV), Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA., Bedoya S; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta Georgia, USA., Aoued H; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Tharp GM; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Pellegrini KL; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Manfredi C; Department of Pediatrics, Division of Pulmonary Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Sorscher E; Department of Pediatrics, Division of Pulmonary Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Mainou B; Center for Childhood Infections and Vaccines (CCIV), Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA., Lobby JL; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA., Kohlmeier JE; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta Georgia, USA., Lowen AC; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta Georgia, USA., Shi PY; Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA., Menachery VD; Department of Microbiology and Immunology, Institute for Human Infection and Immunity, World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, USA., Anderson LJ; Center for Childhood Infections and Vaccines (CCIV), Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA., Grakoui A; Center for Childhood Infections and Vaccines (CCIV), Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA., Bosinger SE; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Suthar MS; Center for Childhood Infections and Vaccines (CCIV), Atlanta, Georgia, USA mehul.s.suthar@emory.edu.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA.; Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Atlanta, Georgia, USA.; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta Georgia, USA.

Publikováno v: Journal of virology [J Virol] 2020 Sep 15; Vol. 94 (19). Date of Electronic Publication: 2020 Sep 15 (Print Publication: 2020).

Unique Signaling Properties of CTAR1 in LMP1-Mediated Transformation

Autor: Raab-Traub, N., Mainou, B. A., Everly, D. N.

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) gene is considered the EBV oncogene as it is necessary for EBV-mediated transformation of B lymphocytes and itself transforms rodent fibroblasts. LMP1 activates the NF-κB, phosphatidylino

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d1ffebe64ecfbdce706868e831a85ddd

Induction of Id1 and Id3 by Latent Membrane Protein 1 of Epstein-Barr Virus and Regulation of p27/Kip and Cyclin-Dependent Kinase 2 in Rodent Fibroblast Transformation

Autor: Raab-Traub, N., Everly, D. N., Mainou, B. A.

Latent membrane protein 1 (LMP1), the Epstein-Barr virus oncoprotein, activates NF-κB, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, and c-Jun N-terminal kinase signaling. To determine global transcriptional changes induced by LMP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f8de2db5ca08a2f416d99aa3a4a8417

Pathogenic Characteristics of an Infection with Canine Influenza Virus and Streptococcus equi subsp. zooepidemicus Alone or in Combination in Mice.

Autor: Zhao, Dan¹ (AUTHOR), Sun, Yaru¹ (AUTHOR), Guo, Jingjing¹ (AUTHOR), Tang, Yuping¹ (AUTHOR), Wang, Zhibo¹ (AUTHOR), Wen, Xia¹ (AUTHOR), Dong, Yuhao¹ (AUTHOR), Liu, Yongjie¹ (AUTHOR)

Publikováno v: Transboundary & Emerging Diseases. 1/17/2024, p1-16. 16p.

From touchdown to transcription: the reovirus cell entry pathway.

Autor: Danthi P; Department of Biology, Indiana University, Bloomington, IN, 47405, USA., Guglielmi KM, Kirchner E, Mainou B, Stehle T, Dermody TS

Publikováno v: Current topics in microbiology and immunology [Curr Top Microbiol Immunol] 2010; Vol. 343, pp. 91-119.